Novo Nordisk Revenue 2010-2022 | NVO

Novo Nordisk revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Novo Nordisk Annual Revenue
(Millions of US $)
2021 $22,401
2020 $19,448
2019 $18,291
2018 $17,099
2017 $16,967
2016 $16,611
2015 $16,060
2014 $15,834
2013 $14,884
2012 $13,483
2011 $12,400
2010 $10,836
2009 $9,567
Novo Nordisk Quarterly Revenue
(Millions of US $)
2022-03-31 $6,338
2021-12-31 $5,916
2021-09-30 $5,650
2021-06-30 $5,356
2021-03-31 $5,480
2020-12-31 $5,157
2020-09-30 $4,856
2020-06-30 $4,432
2020-03-31 $5,003
2019-12-31 $4,798
2019-09-30 $4,511
2019-06-30 $4,523
2019-03-31 $4,458
2018-12-31 $3,934
2018-09-30 $4,331
2018-06-30 $4,388
2018-03-31 $4,446
2017-12-31 $4,446
2017-09-30 $4,205
2017-06-30 $4,236
2017-03-31 $4,080
2016-12-31 $4,284
2016-09-30 $4,131
2016-06-30 $4,171
2016-03-31 $4,025
2015-12-31 $4,234
2015-09-30 $3,995
2015-06-30 $4,010
2015-03-31 $3,820
2014-12-31 $4,161
2014-09-30 $3,960
2014-06-30 $3,975
2014-03-31 $3,737
2013-12-31 $3,957
2013-09-30 $3,643
2013-06-30 $3,746
2013-03-31 $3,539
2012-12-31 $3,653
2012-09-30 $3,336
2012-06-30 $3,364
2012-03-31 $3,130
2011-12-31 $3,211
2011-09-30 $3,093
2011-06-30 $3,088
2011-03-31 $2,878
2010-12-31 $2,978
2010-09-30 $2,905
2010-06-30 $2,721
2010-03-31 $2,451
2009-12-31 $2,586
2009-09-30 $2,483
2009-06-30 $2,379
2009-03-31 $2,223
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $479.231B 18.43
Eli Lilly (LLY) United States $310.959B 36.69
Pfizer (PFE) United States $291.093B 10.15
AbbVie (ABBV) United States $270.615B 11.86
Merck (MRK) United States $238.745B 13.49
Novartis AG (NVS) Switzerland $188.691B 13.73
GlaxoSmithKline (GSK) United Kingdom $111.076B 12.97